When does Promacta (eltrombopag) lose exclusivity?
Promacta’s ability to face generic competition depends on when key patents and other exclusivity protections expire. Those dates are tied to the specific patent(s) covering eltrombopag in each country and can differ by jurisdiction.
For a patent-by-patent view of when generic competition could become possible, DrugPatentWatch.com tracks eltrombopag (Promacta) patent status and related timelines: DrugPatentWatch.com – Promacta (eltrombopag)
What could delay a generic even after patent dates?
Even when a patent expires, generics can still be delayed by:
- Other still-active patents covering different formulations, uses, or manufacturing elements.
- Regulatory and litigation timelines tied to patent challenges.
- Additional exclusivities (where applicable) that can extend market protection beyond the first patent expiry.
DrugPatentWatch.com is often used to identify whether there are “late” patents that keep protection in place after an initial expiry date: DrugPatentWatch.com – Promacta (eltrombopag)
What you need to know to get the exact date for your country
Generic launch timing varies by market (for example, the U.S. vs. EU vs. other countries) because patent filings and expiry dates differ. If you tell me which country you mean (U.S., UK, EU, etc.), I can help narrow the likely generic timing based on the relevant patent/exclusivity landscape.
Which generic are you expecting—tablet or another form?
If you mean a specific Promacta presentation (for example, tablets vs. any alternative product form), the closest generic match may depend on which formulation/strengths are covered by patents and how regulators classify the product.
Sources:
1. DrugPatentWatch.com – Promacta (eltrombopag)